Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes

Research output: Contribution to journalArticle


The present study evaluated the combination of antithymocyte globulin (ATG) and cyclosporine A (CsA) in patients with low-risk myelodysplastic syndromes. Twenty patients (17 with refractory anemia and 3 with refractory anemia with excess blasts) received treatment with rabbit-ATG plus CsA. The overall response rate was 30% (6/20); three of the six responders had a complete response. The responses lasted 2-58 months, with two patients still being in complete remission at 42 and 58 months. Short-lasting cytogenetic remissions were achieved in two patients. ATG was poorly tolerated in patients over 70 years of age. Four out of 20 patients progressed to acute myeloid leukemia within a year. We conclude that immunosuppressive treatment may be a therapeutic option for selected patients with myelodysplastic syndrome.


  • PA Broliden
  • IM Dahl
  • R Hast
  • Bertil Johansson
  • E Juvonen
  • L Kjeldsen
  • A Porwit-MacDonald
  • M Sjoo
  • JM Tangen
  • B Uggla
  • G Oberg
  • E Hellstrom-Lindberg
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Hematology


  • cyclosporine A, MDS, ATG, treatment
Original languageEnglish
Pages (from-to)667-670
Issue number5
Publication statusPublished - 2006
Publication categoryResearch